Accesswire
15 Jun 2026, 10:40 UTC · 15w ago
Verdict
Headline leans bullish. We score PGEN +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA granted orphan drug exclusivity for PAPZIMEOS, preventing the approval of similar RRP treatments until August 2032.
More positive than 99% of claims this week
Long-term study data showed 83% of complete responders maintained their response for at least 36 months without additional treatment.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 93% of claims this week
PAPZIMEOS is already commercially available and being prescribed nationwide in the U.S.
More positive than 79% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company received FDA orphan drug exclusivity for PAPZIMEOS and released encouraging long-term clinical durability data.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
4h ago
+92.4%
Price agrees with the score
$8.56 vs $4.45 close before publication (Jun 12) · not market-adjusted
PGEN chart →
